{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:29:48Z","timestamp":1786350588641,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We assessed whether oral acetazolamide (ACZ) increases diuresis and reduces chloride loss when given alongside high-dose intravenous (IV) furosemide in patients admitted to hospital with HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      ADA-HF was a single-centre, open-label, randomised controlled trial. Patients were randomised to ACZ 250\u00a0mg twice daily plus high-dose (240\u00a0mg per day) IV furosemide infusion (standard of care (SoC)) versus SoC alone for 4\u00a0days. The co-primary endpoints were (1) daily net fluid loss between baseline and day 4 and (2) change in serum chloride level from baseline to day 4. A total of 46 patients (median age, 76; 65% male; median N-terminal pro-B-type natriuretic peptide, 4097\u00a0ng\/L) from a screened population of 207 were randomised (23 to ACZ, 23 to SoC). The median daily net fluid loss was 1073\u00a0mL (1st\u20133rd quartile range 682\u20131419\u00a0mL) in the ACZ arm vs. 1029\u00a0mL (201\u20131432\u00a0mL) in the SoC arm (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.51). There was no change in serum chloride concentration in the ACZ arm, whereas chloride fell by 7 (2\u201310) mmol\/L in the SoC arm (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The number of adverse and serious adverse events ((S)AE) was numerically greater in the ACZ arm (51 events in 16 patients vs. 29 events in 10 patients,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.24). Overall, 8 patients (30%) experienced (S)AEs possibly related to ACZ, and two of whom withdrew from the trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Acetazolamide has a significant \u201cchloride-sparing\u201d effect in patients given high-dose IV furosemide. However, ACZ did not significantly increase diuresis, and side effects from oral ACZ were frequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration.<\/jats:title>\n                    <jats:p>ISRCTN13060336; 9\/2\/2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p>\n                      <jats:bold>A<\/jats:bold>\n                      change in fluid balance and\n                      <jats:bold>B<\/jats:bold>\n                      change in serum chloride; HF, heart failure; ACZ, acetazolamide; SoC, standard of care; RCT, randomised controlled trial; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02915-5","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:52:54Z","timestamp":1777287174000},"page":"1675-1685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ADA-HF: acetazolamide as a chloride sparing diuretic in patients admitted to hospital with heart failure"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4339-3062","authenticated-orcid":false,"given":"J. J.","family":"Cuthbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S. M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ajith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Pinhol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Baffour Korsah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bulemfu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Constable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"10","key":"2915_CR1","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/ejhf.1247","volume":"20","author":"JJ Cuthbert","year":"2018","unstructured":"Cuthbert JJ, Pellicori P, Rigby A et al (2018) Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. Eur J Heart Fail 20(10):1426\u20131435. https:\/\/doi.org\/10.1002\/ejhf.1247","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2915_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ehjacc\/zuab097","volume":"11","author":"JJ Cuthbert","year":"2022","unstructured":"Cuthbert JJ, Brown OI, Urbinati A et al (2022) Hypochloraemia following admission to hospital with heart failure is common and associated with an increased risk of readmission or death: a report from OPERA-HF. Eur Heart J Acute Cardiovasc Care 11(1):43\u201352. https:\/\/doi.org\/10.1093\/ehjacc\/zuab097","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"2","key":"2915_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40119-020-00194-3","volume":"9","author":"JJ Cuthbert","year":"2020","unstructured":"Cuthbert JJ, Bhandari S, Clark AL (2020) Hypochloraemia in patients with heart failure: causes and consequences. Cardiol Ther 9(2):333\u2013347. https:\/\/doi.org\/10.1007\/s40119-020-00194-3","journal-title":"Cardiol Ther"},{"issue":"13","key":"2915_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P et al (2022) Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 387(13):1185\u20131195. https:\/\/doi.org\/10.1056\/NEJMoa2203094","journal-title":"N Engl J Med"},{"issue":"11","key":"2915_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/ejhf.1478","volume":"21","author":"FH Verbrugge","year":"2019","unstructured":"Verbrugge FH, Martens P, Ameloot K et al (2019) Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail 21(11):1415\u20131422. https:\/\/doi.org\/10.1002\/ejhf.1478","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2915_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40261-017-0577-1","volume":"37","author":"T Imiela","year":"2017","unstructured":"Imiela T, Budaj A (2017) Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study. Clin Drug Investig 37(12):1175\u20131181. https:\/\/doi.org\/10.1007\/s40261-017-0577-1","journal-title":"Clin Drug Investig"},{"issue":"12","key":"2915_CR7","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16526","volume":"133","author":"A Kosiorek","year":"2023","unstructured":"Kosiorek A, Urban S, Detyna J, Biegus J, Hurkacz M, Zymli\u0144ski R (2023) Diuretic, natriuretic, and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload: a single-center, prospective, randomized study. Pol Arch Intern Med 133(12):16526. https:\/\/doi.org\/10.20452\/pamw.16526","journal-title":"Pol Arch Intern Med"},{"issue":"10","key":"2915_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011749","volume":"17","author":"J Van den Eynde","year":"2024","unstructured":"Van den Eynde J, Martens P, Dauw J et al (2024) Serum chloride and the response to acetazolamide in patients with acute heart failure and volume overload: a post hoc analysis from the ADVOR trial. Circ Heart Fail 17(10):e011749. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011749","journal-title":"Circ Heart Fail"},{"issue":"2","key":"2915_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeaf019","volume":"5","author":"JJ Cuthbert","year":"2025","unstructured":"Cuthbert JJ, Luo E, Ahmed ASM et al (2025) Rationale and design of the acetazolamide as a chloride sparing diuretic in patients admitted with heart failure (ADA-HF) trial. Eur Heart J Open 5(2):oeaf019. https:\/\/doi.org\/10.1093\/ehjopen\/oeaf019","journal-title":"Eur Heart J Open"},{"key":"2915_CR10","unstructured":"National Institute for Health and Care Excellence. Acute heart failure: diagnosis and management. CG187. 2014. Available at: https:\/\/www.nice.org.uk\/guidance\/cg187. [Accessed 11th December 2019]"},{"issue":"31","key":"2915_CR11","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","volume":"44","author":"SE Yeoh","year":"2023","unstructured":"Yeoh SE, Osmanska J, Petrie MC et al (2023) Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J 44(31):2966\u20132977. https:\/\/doi.org\/10.1093\/eurheartj\/ehad341","journal-title":"Eur Heart J"},{"issue":"5","key":"2915_CR12","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1002\/ehf2.14021","volume":"9","author":"N Sato","year":"2022","unstructured":"Sato N, Uno S, Kurita Y, Kim S, OPTION-HF Investigators (2022) Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure. ESC Heart Fail 9(5):3275\u20133286. https:\/\/doi.org\/10.1002\/ehf2.14021","journal-title":"ESC Heart Fail"},{"issue":"3","key":"2915_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","volume":"8","author":"ZL Cox","year":"2020","unstructured":"Cox ZL, Hung R, Lenihan DJ, Testani JM (2020) Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail 8(3):157\u2013168. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.012","journal-title":"JACC Heart Fail"},{"issue":"11","key":"2915_CR14","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/10600280231154603","volume":"57","author":"JD Addison","year":"2023","unstructured":"Addison JD, Peterson EJ, Meyenburg L (2023) Intravenous or oral acetazolamide for treatment of diuretic-induced alkalosis in patients with heart failure. Ann Pharmacother 57(11):1241\u20131247. https:\/\/doi.org\/10.1177\/10600280231154603","journal-title":"Ann Pharmacother"},{"issue":"8","key":"2915_CR15","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jchf.2024.04.014","volume":"12","author":"AR Abbo","year":"2024","unstructured":"Abbo AR, Gruber A, Volis I et al (2024) Diuresis efficacy in ambulatory congested heart failure patients: intrapatient comparison of 3 diuretic regimens (DEA-HF). JACC Heart Fail 12(8):1396\u20131405. https:\/\/doi.org\/10.1016\/j.jchf.2024.04.014","journal-title":"JACC Heart Fail"},{"issue":"9","key":"2915_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA et al (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa1005419","journal-title":"N Engl J Med"},{"issue":"2","key":"2915_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11897-024-00644-2","volume":"21","author":"JJ Cuthbert","year":"2024","unstructured":"Cuthbert JJ, Cleland JGF, Clark AL (2024) Diuretic treatment in patients with heart failure: current evidence and future directions-part II: combination therapy. Curr Heart Fail Rep 21(2):115\u2013130. https:\/\/doi.org\/10.1007\/s11897-024-00644-2","journal-title":"Curr Heart Fail Rep"},{"key":"2915_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3374","author":"P Pellicori","year":"2024","unstructured":"Pellicori P, Cuthbert JJ, Clark AL, Cleland JGF (2024) Managing water and salt balance in heart failure: is there anything else to consider other than diet and diuretics? Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3374","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2915_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jchf.2023.01.011","volume":"11","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Felker GM (2023) Considering addition of acetazolamide to loop diuretics as treatment for acute heart failure: ADVOR reappraisal. JACC Heart Fail 11(3):365\u2013367. https:\/\/doi.org\/10.1016\/j.jchf.2023.01.011","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2915_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000557","volume":"7","author":"CN Schmickl","year":"2020","unstructured":"Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A (2020) Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence. BMJ Open Respir Res 7(1):e000557. https:\/\/doi.org\/10.1136\/bmjresp-2020-000557","journal-title":"BMJ Open Respir Res"},{"issue":"14","key":"2915_CR21","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1093\/cvr\/cvad148","volume":"119","author":"JJ Cuthbert","year":"2023","unstructured":"Cuthbert JJ, Cleland JGF (2023) Should we resurrect acetazolamide as a diuretic for congestion due to heart failure? Cardiovasc Res 119(14):e149\u2013e151. https:\/\/doi.org\/10.1093\/cvr\/cvad148","journal-title":"Cardiovasc Res"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02915-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:55:22Z","timestamp":1786348522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02915-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2915"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02915-5","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}